NUCLIDIUM AG successfully raised CHF 79 million (EUR 84 million) in a Series B financing round to advance its copper-based theranostic platform for cancer diagnosis and treatment.

Target Company Overview

NUCLIDIUM AG is a clinical-stage biopharmaceutical company focused on developing a proprietary theranostic platform based on copper isotopes for cancer diagnosis and treatment. The company's innovative approach utilizes Copper-61 for diagnostic imaging and Copper-67 for therapeutic applications, providing a differentiated solution that addresses current limitations in radiotheranostics. With operational bases in Switzerland and Germany, NUCLIDIUM combines advanced chemistry, clinical expertise, and strategic manufacturing capabilities to offer scalable and accessible theranostic solutions worldwide, particularly targeting unmet medical needs in oncology and women's health.

Industry Overview in Switzerland

Switzerland boasts a robust life sciences sector, characterized by high levels of innovation and investment. The country is home to several leading pharmaceutical and biotech companies, benefiting from a strong research and development infrastructure supported by well-established academic institutions. This environment fosters collaboration between industry and academia, paving the way for cutting-edge advancements in medical technology.

The Swiss regulatory landscape is notably conducive to life sciences companies, facilitating a streamlined process for clinical trials and product approvals. With